Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jun 1, 2012

NEW YORK (GenomeWeb News) – David Rimoin, director of the Cedars-Sinai Medical Genetics Institute, has died from pancreatic cancer at the age of 75. For 18 years prior to founding the Medical Genetics Institute in 2004, Rimoin served as chair of the Cedars-Sinai Department of Pediatrics. He also previously served as chief of the Division of Medical Genetics at Harbor-UCLA Medical Center and was director of the Genetics Clinic at the Washington University School of Medicine in St. Louis.

From 1979 to 1983, Rimoin served as founding president of the American Board of Medical Genetics. He was founding president of the American College of Medical Genetics and Genomics from 1992 to 1998, and then served as president of the ACMG Foundation for Genetic and Genomic Medicine from 1998 to 2002. Additionally, he was a member of the Institute of Medicine, a master in the American College of Physicians and an Honorary Life member of Little People of America.


CLC Bio said this week that it has appointed Richard Lussier as director of business for the Americas region. He has worked in life sciences sales and commercial operations, most recently as VP of worldwide sales at RainDance Technologies. He formerly held leadership positions in sales, service, and support at Solexa, Fluidigm, Applied Biosystems, and Celera Genomics.


NanoString said this week that it has hired Bruce Seeley to lead a new diagnostics business unit. In his position as senior vice president and general manager of diagnostics, Seeley will oversee the marketing of NanoString's breast cancer test to pathologists and oncologists. Seeley previously was executive VP of Seattle Genetics' commercial operations, he was senior director of marketing at Genentech, and he worked at Aventis Pharma as senior director of new product commercialization and marketing. He also held sales and marketing titles at Rhone-Poulenc Rorer and Bristol-Myers Squibb.


According to a filing with the US Securities and Exchange Commission, Nanosphere's shareholders this week re-elected six nominees to continue serving on the company's board of directors, including William Moffitt; Mark Slezak; André de Bruin; Chad Mirkin; Lorin Randall; and William White.


David Altshuler has been appointed to the board of directors at Vertex Pharmaceuticals. He is a professor of genetics and medicine at Harvard Medical School, where he has served on the faculty since 2000. He is also a founding member of the Broad Institute and is on the faculty of Massachusetts General Hospital in its Department of Molecular Biology, the Diabetes Unit of the Department of Medicine, and the Center for Human Genetic Research.


Response Genetics said in a recent SEC filing that VP and General Counsel Denise McNairn will resign from her positions at the company as of June 8.


Biomarker developer Critical Diagnostics has hired Richard Hughes to be VP of business development in Europe, a post he will operate out of Bristol, England. Hughes has spent over 15 years working in medical diagnostics, including terms at Alere, British Biocell, Oxford Immunotech, and Microvisk.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.